Use-inspired Biomaterials & Integrated Nano Delivery (U-BiND) Systems Laboratory, Department of Pharmaceutical Sciences, Wayne State University, Detroit, MI, USA.
Department of Pharmaceutical Sciences, Wayne State University, Detroit, MI, USA; Molecular Therapeutics Program, Karmanos Cancer Institute, Detroit, MI, USA.
Drug Discov Today. 2023 Nov;28(11):103761. doi: 10.1016/j.drudis.2023.103761. Epub 2023 Sep 1.
Current treatment strategies for triple-negative breast cancer (TNBC) are based upon conventional chemotherapy, immunotherapy, or a combination of both. The treatment regimen for chemotherapy is often a combination of two or more drugs, either dose dense or low dose for synergy. Anthracyclines, alkylating agents, antimicrotubule agents, and antimetabolites for early-stage TNBC; and antimetabolites, non-taxane microtubule inhibitors, and cross-linker platinums for late-stage TNBC are usually administered in the clinical setting. Newer options for patients with advanced TNBC, such as poly (ADP-ribose) polymerase (PARP) inhibitors and immune checkpoint inhibitors, have recently emerged for cases where surgery is not a viable option and the disease has metastasized. This review outlines the current trends in hypoxia-inspired treatment strategies for TNBC with a focus on clinical trials.
目前针对三阴性乳腺癌（TNBC）的治疗策略基于常规化疗、免疫疗法或两者的联合应用。化疗的治疗方案通常是两种或多种药物的联合应用，无论是剂量密集型还是低剂量以发挥协同作用。蒽环类药物、烷化剂、微管蛋白抑制剂和抗代谢物用于早期 TNBC；而抗代谢物、非紫杉烷微管抑制剂和交联铂类药物用于晚期 TNBC，通常在临床环境中使用。对于晚期 TNBC 患者的新选择，如聚（ADP-核糖）聚合酶（PARP）抑制剂和免疫检查点抑制剂，最近已经出现，适用于手术不可行且疾病已经转移的情况。本综述概述了基于缺氧的 TNBC 治疗策略的当前趋势，重点是临床试验。
Zotero 插件